Semax Research: What 240 Studies Show (2026) | RetatrutideCompare

Semax — 240 studies indexed on PubMed. Increases BDNF and NGF in hippocampus; activates dopaminergic and serotonergic systems; melanocortin receptor activity. Half-life: ~30 minutes (intranasal). FDA status: Not FDA-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Semax?

There are approximately 240 studies indexed on PubMed that mention Semax (MEHFPGP, ACTH (4-7) Pro-Gly-Pro), based on a search last updated 2026-06-18.

Is Semax FDA-approved?

FDA status: Not FDA-approved.

How does Semax work?

Increases BDNF and NGF in hippocampus; activates dopaminergic and serotonergic systems; melanocortin receptor activity.

Increases BDNF and NGF in hippocampus; activates dopaminergic and serotonergic systems; melanocortin receptor activity.

Reference facts

Also known as
MEHFPGP, ACTH (4-7) Pro-Gly-Pro
Category
Nootropic & Cognitive
Mechanism of action
Increases BDNF and NGF in hippocampus; activates dopaminergic and serotonergic systems; melanocortin receptor activity.
Targets
BDNF/NGF up-regulation, Melanocortin receptors
Indications under research or approved
Approved Russia (ischemic stroke, cognitive disorders); not US-approved
Regulatory status (reference entry)
Not FDA-approved
Half-life
~30 minutes (intranasal)
Sequence
MEHFPGP
Sequence notes
Heptapeptide. ACTH (4-7) fragment Met-Glu-His-Phe extended with the proline-glycine-proline tail used in Russian peptide design to resist enzymatic degradation.
Molecular weight (Da)
813
First reported
1981

Primary References

Explore research articles about Semax

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.